



31/Reissue  
decl 1/172

Patent  
Attorney's Docker No. 033364-280

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of	)	<b>MAILSTOP: REISSUE</b>
Patrick AHL et al.	)	
Application No.: 09/398,934 (Reissue application of U.S. Patent No. 5,662,930)	)	Group Art Unit: 1615
	)	Examiner: Gollamudi S. Kishore
Filed: September 1, 1999	)	Confirmation No.: 1677
For: REDUCTION OF LIPOSOME- INDUCED ADVERSE PHYSIOLOGICAL REACTIONS	)	

**RECEIVED**  
OCT 06 2003  
TECH CENTER 1600/2900

**REISSUE APPLICATION DECLARATION BY THE ASSIGNEE**  
**PURSUANT TO 37 C.F.R. § 1.172**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

I, Jean Duvall, hereby declare that:

My mailing address, citizenship, and position title are stated below next to my name. I am authorized to act on behalf of the current assignee, Elan Pharmaceuticals, Inc. The entire title to the patent identified below is vested in Elan Pharmaceuticals, Inc. as evidenced by the chain of title as described in the Statement Under 37 C.F.R. § 3.73(b) submitted herewith.

The names, last-known addresses and citizenships of Patentees are as follows:

Patrick L. Ahl, 2E Brookline Court, Princeton, NJ 08536, US

Suresh Bhatia, B-165 Sarita Vihar, Mathura Road, New Delhi, 110044, IN

(05/03)

Application No. 09/398,934  
Attorney's Docket No. 033364-280  
Page 2

Sharma R. Minchey, 1693 Camp Hill Road, Lafayette, TN 37083, US

Andrew S. Janoff, 560 Countess Drive, Yardley, PA 19067, US

I believe the above patentees to be the original, joint inventors of the subject matter which is described and claimed in the patent, for which a reissue patent is sought on the invention entitled REDUCTION OF LIPOSOME-INDUCED ADVERSE PHYSIOLOGICAL REACTIONS, the specification of which was filed on September 1, 1999, as Reissue Application Number 09/398,934 and was amended on September 1, 1999; November 2, 2000; October 26, 2001, by way of a Request for Continued Examination, which requested entry of the amendment filed on August 27, 2001; September 23, 2002; and in the Reply & Amendment submitted herewith.

I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability as defined in 37 C.F.R. § 1.56.

I verily believe the original patent to be wholly or partly inoperative or invalid, for the reasons described below. At least one error upon which reissue is based is described as follows. Original Claim 14 may be considered indefinite as improperly depending from Claim 12, rather than Claim 13. Accordingly, the recitation of "functional group" in Claim 14 lacks antecedent basis. This error was corrected in the Amendment filed September 23, 2002. Additionally, Claim 16 may be considered indefinite as containing an improper Markush group. A rejection of Claim 16 under 35 U.S.C. § 112, second

(05/03)

Application No. 09/398,934  
Attorney's Docket No. 033364-280  
Page 3

paragraph, was made in the Official Action issued on April 25, 2002, in the present reissue application. Claim 16 was amended and new Claims 54-57 were added in the Amendment filed September 23, 2002, to correct this error.

All errors corrected in this reissue application arose without any deceptive intention on the part of the Applicants. Moreover, none of the above errors were brought to the attention of Applicants during prosecution of the original patent.

This Reissue Declaration by Assignee Pursuant to 37 C.F.R. § 1.172 is proper because the present reissue application no longer seeks to broaden the scope of the original patent.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine and imprisonment, or both, under 18 U.S.C. § 1001, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this declaration is directed.

Respectfully submitted,

Date: Sept. 26, 2003

By: Jean Duvall

Jean Duvall  
Executive Vice President and General Counsel  
Elan Pharmaceuticals, Inc.  
800 Gateway Blvd.  
South San Francisco, CA 94080  
U.S. citizen

(05/03)



Patent  
Attorney's Docket No. 033364-280

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of	)	MAILSTOP: REISSUE
	)	
Patrick AHL et al.	)	Group Art Unit: 1615
	)	
Application No.: 09/398,934 (Reissue	)	Examiner: Gollamudi S. Kishore
application of U.S. Patent No. 5,662,930)	)	
	)	Confirmation No.:1677
Filed: September 1, 1999	)	
	)	
For: REDUCTION OF LIPOSOME-	)	
INDUCED ADVERSE	)	
PHYSIOLOGICAL REACTIONS	)	

**CONSENT OF ASSIGNEE**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The undersigned states that she is empowered to execute this Consent on behalf of Elan Pharmaceuticals, Inc., assignee of the entire interest in U.S. Patent No. 5,662,930, and the above-identified reissue application. The entire title to the patent and subsequent reissue application is vested in Elan Pharmaceuticals, Inc. as evidenced by the chain of title as described in the Statement Under 37 C.F.R. §3.73(b) submitted herewith.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine and imprisonment, or both, under 18 U.S.C. § 1001, and that

(05/03)

Application No. 09/398,934  
Attorney's Docket No. 033364-280  
Page 2

such willful false statements may jeopardize the validity of the application, any patent  
issuing thereon, or any patent to which this Consent is directed.

Respectfully submitted,

Date: Sept. 26, 2003

By: Jean Duvall

Jean Duvall  
Executive Vice President and General Counsel  
Eli Lilly Pharmaceuticals, Inc.  
800 Gateway Blvd.  
South San Francisco, CA 94080  
U.S. citizen

(05/03)



PTO/SB/96 (6-98)  
Approved for use through 09/30/2000, OMB 0651-0031  
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Attorney's Docket No. 033384-280

**STATEMENT UNDER 37 C.F.R. § 3.73(b)**

Applicant/Patent Owner: Elan Pharmaceuticals, Inc.

Application No./Patent No.: 09/398,934

Filed/Issue Date: September 1, 1999

Entitled: REDUCTIONS OF LIPOSOME-INDUCED ADVERSE PHYSIOLOGICAL REACTIONS

Elan Pharmaceuticals, Inc.

(Name of Assignee)

a Corporation

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of an undivided part interest

in the patent application/patent identified above by virtue of either:

- A. ☐ An assignment from the inventor(s) of the patent application identified above. The assignment was recorded in the Patent and Trademark Office at Reel        Frame       , or for which a copy thereof is attached.

OR

- B. ☒ A chain of title from the inventor(s), of the patent application identified above, to the current assignee as shown below:

1. From: All inventors To: The Liposome Company, Inc.  
The document was recorded in the Patent and Trademark Office at Reel 7097 Frame 0350, or for which a copy thereof is attached.
2. From: The Liposome Company, Inc. To: Elan Pharmaceuticals, Inc.  
The document was recorded in the Patent and Trademark Office at Reel 12858 Frame 601, or for which a copy thereof is attached.
3. From:        To:         
The document was recorded in the Patent and Trademark Office at Reel        Frame       , or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☐ Copies of assignments or other documents in the chain of title are attached.

(NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the PTO. See (MPEP 302-302.8)

The undersigned (whose title is supplied below) is empowered to sign this statement on behalf of the assignee.

Date: Sept. 26, 2003

Jean Duvall  
Signature  
Jean Duvall  
Typed or printed name  
Executive Vice President and General Counsel  
Title